References
- Adams AB, Newell KA. (2012). B cells in clinical transplantation tolerance. Semin Immunol, 24, 92–5
- Barama A, Oza U, Panek R, et al. (2000). Effect of recipient sensitization (peak PRA) on graft outcome in haploidentical living related kidney transplants. Clin Transplant, 14, 212–17
- Basu A, Falcone J, Dvorchik I, et al. (2011). Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression. Ann Transplant, 16, 5–13
- Becker YT, Becker BN, Pirsch JD, Sollinger HW. (2004). Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant, 4, 996–1001
- Becker YT, Samaniego-Picota M, Sollinger HW. (2006). The emerging role of rituximab in organ transplantation. Transpl Int, 19, 621–8
- Bouaziz JD, Calbo S, Maho-Vaillant M, et al. (2010). IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol, 40, 2686–91
- Cai J, Terasaki PI. (2010). The current trend of induction and maintenance treatment in patient of different PRA levels: A report on OPTN/UNOS Kidney Transplant Registry data. Clin Transplant, 2010, 45–52
- Clatworthy MR, Watson CJ, Plotnek G, et al. (2009). B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med, 360, 2683–5
- Cooper JE, Gralla J, Cagle L, et al. (2011). Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation, 91, 1103–9
- de Wit J, Souwer Y, Jorritsma T, et al. (2010). Antigen-specific B cells reactivate an effective cytotoxic T cell response against phagocytosed Salmonella through cross-presentation. PLoS One, 5, e13016
- Domingues EM, Matuck T, Graciano ML, et al. (2010). Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant. Clin Transplant, 24, 821–9
- Donaldson PT, Williams R. (1997). Cross-matching in liver transplantation. Transplantation, 63, 789–94
- Einecke G, Sis B, Reeve J, et al. (2009). Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant, 9, 2520–31
- Faguer S, Kamar N, Guilbeaud-Frugier C, et al. (2007). Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation, 83, 1277–80
- Gartner V, Eigentler TK, Viebahn R. (2006). Plasma cell-rich rejection processes in renal transplantation: Morphology and prognostic relevance. Transplantation, 81, 986–91
- Gloor JM, Winters JL, Cornell LD, et al. (2010). Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant, 10, 582–9
- Heidt S, Hester J, Shankar S, et al. (2012). B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells. Am J Transplant, 12, 1784–92
- Hippen BE, DeMattos A, Cook WJ, et al. (2005). Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant, 5, 2248–52
- Hoshino J, Kaneku H, Everly MJ, et al. (2012). Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation, 93, 1173–8
- Kelishadi SS, Azimzadeh AM, Zhang T, et al. (2010). Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys. J Clin Invest, 120, 1275–84
- Kopchaliiska D, Zachary AA, Montgomery RA, Leffell MS. (2009). Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients. Transplantation, 87, 1394–401
- Kozlowski T, Andreoni K. (2011). Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? Ann Transplant, 16, 19–25
- Lefaucheur C, Nochy D, Hill GS, et al. (2007). Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant, 7, 832–41
- Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. (2008). Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant, 8, 324–31
- Liu C, Noorchashm H, Sutter JA, et al. (2007). B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med, 13, 1295–8
- Loupy A, Suberbielle-Boissel C, Zuber J, et al. (2010). Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation, 89, 1403–10
- Marfo K, Ling M, Bao Y, et al. (2012). Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation, 94, 345–51
- Matas AJ, Smith JM, Skeans MA, et al. (2014). OPTN/SRTR 2012 annual data report: Kidney. Am J Transplant, 14, 11–44
- Michaels PJ, Kobashigawa J, Laks H, et al. (2001). Differential expression of RANTES chemokine, TGF-beta, and leukocyte phenotype in acute cellular rejection and quilty B lesions. J Heart Lung Transplant, 20, 407–16
- Mullins P, Solis E, Prat A, et al. (1989). Cardiac and lung transplantation. Curr Opin Immunol, 2, 837–41
- Munoz AS, Rioveros AA, Cabanayan-Casasola CB, et al. (2008). Rituximab in highly sensitized kidney transplant recipients. Transplant Proc, 40, 2218–21
- Nickeleit V, Andreoni K. (2007). The classification and treatment of antibody-mediated renal allograft injury: Where do we stand? Kidney Int, 71, 7–11
- Pankewycz O, Leca N, Kohli R, et al. (2011). Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transplant Proc, 43, 462–5
- Paramesh AS, Zhang R, Baber J, et al. (2010). The effect of HLA mismatch on highly sensitized renal allograft recipients. Clin Transplant, 24, E247–52
- Parsons RF, Redfield RR III, Rodriguez E, et al. (2012). Primary B cell repertoire remodeling to achieve humoral transplantation tolerance. Semin Immunol, 24, 109–14
- Rhee J, Al-Mana N, Freeman R. (2009). Immunosuppression in high-risk transplantation. Curr Opin Organ Transplant, 14, 636–42
- Smith JD, Danskine AJ, Laylor RM, et al. (1993). The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol, 1, 60–5
- Stroopinsky D, Katz T, Rowe JM, et al. (2012). Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother, 61, 1233–41
- Takagi T, Ishida H, Shirakawa H, et al. (2010a). Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transplant Immunol, 23, 220–3
- Takagi T, Ishida H., Shirakawa H, et al. (2010b). Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation, 89, 1466–70
- Tchao NK, Turka LA. (2012). Lymphodepletion and homeostatic proliferation: Implications for transplantation. Am J Transplant, 12, 1079–90
- Terasaki PI, Cai J. (2005). Humoral theory of transplantation: Further evidence. Curr Opin Immunol, 17, 541–5
- Thaunat O. (2011). Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation, 92, 121–6
- Tsai EW, Rianthavorn P, Gjertson DW, et al. (2006). CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation, 82, 1769–73
- Tyden G, Kumlien G, Genberg H, et al. (2005). ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant, 5, 145–8
- Vo AA, Peng A, Toyoda M, et al. (2010). Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation, 89, 1095–102
- Wehner J, Morrell CN, Reynolds T, et al. (2007). Antibody and complement in transplant vasculopathy. Circ Res, 100, 191–203
- Wiebe C, Gibson IW, Blydt-Hansen TD, et al. (2012). Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant, 12, 1157–67
- Yin H, Wan H, Hu XP, et al. (2011). Rituximab induction therapy in highly sensitized kidney transplant recipients. Chin Med J, 124, 1928–32
- Zaltzman JS, Boucher A, Busque S, et al. (2005). A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients. Clin Transplant, 19, 26–32
- Zarkhin V, Li L, Kambham N, et al. (2008). A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant, 8, 2607–17